

IN THE UNITED STATES DISTRICT COURT FOR THE
NORTHERN DISTRICT OF ALABAMA
~~BIRMINGHAM~~ DIVISION
SOUTHERN

FILED
04 NOV 10 PM 1:37
U.S. DISTRICT COURT
N.D. OF ALABAMA

DR

UNITED STATES OF AMERICA,)
ex rel, EMAD BALKASH,)
)
Plaintiffs/Relator)
)
v.)
)
TENET HEALTHCARE)
CORPORATION, BROOKWOOD)
MEDICAL CENTER, and)
LABORATORY CORPORATION)
OF AMERICA,)
)
Defendants)

CIVIL ACTION
FILE NO. _____

CV-04-HS-3193-S

COMPLAINT

This is an action brought on behalf of the United States of America by EMAD BALKASH ("Relator") against the Defendants pursuant to the qui tam provisions of the Civil False Claims Act 31 U.S.C. §§ 3729-33.

The Defendants have billed the Federal Government millions of dollars for blood products and services that were not provided. The blood products and services referenced herein were paid for federally-funded insurance programs, such as Medicare, Medicaid, the Civilian Health and Medical Program of the Uniform

Services (“CHAMPUS”), and the Civilian Health and Medical Program of the Veterans Administration (“CHAMPVA”).

THE PARTIES

1.

Relator is a citizen of the United States of America, who resides in Duluth, Georgia. He has a Bachelor of Science degree in Biochemistry and a Bachelor of Science degree in Medical Technology.

2.

Relator obtained a Master of Science degree in Clinical Laboratory Services from the University of Alabama at Birmingham in 1998. He supplemented his degrees by obtaining a Board certification from the American College of Clinical Pathologists. Relator also holds a specialty Board certification in Blood Banking that was also awarded by the American College of Clinical Pathologists.

3.

Relator managed the Blood Bank at Brookwood Medical Center (“Blood Bank”) from September 28, 1998 through April 2004.

4.

Relator believes and therefore avers that Defendant Tenant Healthcare Corporation (“Tenet”) owns and operates hospitals and related healthcare services across the United States.

5.

Relator avers that Tenet owns approximately 89 acute care hospitals in 14 states. One of the hospitals that Tenet owns in its “Florida-Alabama Region” is Defendant Brookwood Medical Center (“Brookwood Hospital”).

6.

Brookwood Hospital is located in Homewood, Alabama, which is a suburb of Birmingham, Alabama.

7.

Relator avers that Brookwood Hospital has approximately 586 beds. It utilizes more than 750 Board-certified physicians and employs approximately 1,600 people.

8.

During his term of employment at Brookwood Hospital, Relator was employed by Defendant Laboratory Corporation of America (“LabCorp”).

9.

Relator avers that Defendant Tenet and/or Defendant Brookwood Hospital contracted with Defendant LabCorp regarding the provision of multiple laboratory services to be provided by LabCorp to Brookwood Hospital patients.

10.

Accordingly, from September 1998 through April 2004, Relator acted as the manager of the Blood Bank while employed by the Defendant LabCorp at facilities owned and operated by Defendants Brookwood Hospital and Tenet.

11.

Relator believes and therefore avers that Defendants bill studies for Blood Bank services and products to its patients, including patients covered under various federally-funded insurance programs, such as the Health Insurance Program for the Elderly and Disabled, commonly referred to as the Medicare Program, 42 U.S.C. § 1395, et seq.

12.

Relator believes and therefore avers that Defendants bill studies for Blood Bank services and products to its patients, including patients covered under various federally-funded insurance programs, such as the Health Insurance Program for the Elderly and Disabled, commonly referred to as the Medicaid Program, 42 U.S.C. § 1396, et seq.

JURISDICTION AND VENUE

13.

This Court has subject matter jurisdiction over this action pursuant to 28 U.S.C. §§ 1331 and 1345, which is a “law of the United States.”

14.

This Court has personal jurisdiction over Defendants because they conduct business within the Northern District of Alabama. Each of the Defendants transacts business within the Northern District of Alabama and performs services and submits claims to Federal healthcare programs for services rendered in the Northern District of Alabama.

15.

Venue is proper within the Northern District of Alabama pursuant to 28 U.S.C. § 1391(a)(1) and (2) because Defendants have offices within the Northern District of Alabama and have performed numerous acts proscribed by the False Claims Act ("FCA") 31 U.S.C. § 3729-33 within the Northern District of Alabama.

THE APPLICABLE LAW

The False Claims Act

16.

The False Claim Act (FCA) provides, in pertinent part:

(a) Any person who (1) knowingly presents, or causes to be presented, to an officer or employee of the United States Government or a member of the Armed Forces of the United States a false or fraudulent claim for payment or approval; (2) knowingly makes, uses, or causes to be made or used, a false record or

statement to get a false or fraudulent claim paid or approved by the Government; (3) knowingly makes, uses, or causes to be made or used, a false record or statement to conceal, avoid, or decrease an obligation to pay or transmit money or property to the Government, is liable to the United States Government for a civil penalty of not less than \$5,500 and not more than \$11,000, plus 3 times the amount of damages which the Government sustains because of the act of that person

(b) For purposes of this section, the terms “knowing” and “knowingly” mean that a person, with respect to information (1) has actual knowledge of the information; (2) acts in deliberate ignorance of the truth or falsity of the information; or (3) acts in reckless disregard of the truth or falsity of the information, and no proof of specific intent to defraud is required.

FACTUAL BACKGROUND ON THE FEDERALLY-FUNDED HEALTH INSURANCE PROGRAMS

The Medicare Program

17.

In 1965, Congress enacted Title XVIII of the Social Security Act, which established the Medicare Program to provide health insurance for the elderly and disabled. Payments from the Medicare Program come from a trust fund – known as the Medicare Trust Fund – which is funded through payroll deductions taken from the work force, in addition to government contributions.

18.

The Medicare Program is administered through the United States Department of Health and Human Services ("HHS") and, specifically, the Centers for Medicare and Medicaid Services (CMS), an agency of HHS.

19.

Much of the daily administration and operation of the Medicare Program is managed through fiscal intermediaries, typically private insurance companies, that contract with the CMS. These private insurance companies, or "Medicare Carriers," are charged with and responsible for accepting Medicare claims, determining coverage, and making payments from the Medicare Trust Fund.

20.

Over the last thirty years, the Medicare Program has enabled the elderly and disabled to obtain necessary medical services from medical providers throughout the United States.

21.

Critical to the continued success of the Medicare Program are the fundamental concepts that medical providers only bill the Medicare Trust Fund for medical treatments or services that are actually provided to patients and that are legitimately medically indicated and necessary. It is also imperative that medical providers not take advantage of their elderly and disabled patients.

22.

Physicians and other health care providers, when submitting a claim for payment for medical treatment or services provided to a Medicare recipient must certify that the treatment or service was actually provided and “reasonable and necessary for the diagnosis or treatment of illness or injury.” Soc. Sec. Act § 1862(a)(1)(A).

23.

The fundamental concept that only treatments or services that are provided to the patient and medically necessary be billed is essential to the continued viability of the Medicare Program and the future viability and solvency of the Medicare Trust Fund.

**Other Federally Funded
Health Insurance Programs**

24.

Medicaid is a joint federal-state program that provides care for indigent and disabled people. Although the Medicaid program is administered by the states, it is funded in a significant part by the federal government.

25.

The Civilian Health and Medical Program of the Uniformed Services (“CHAMPUS”) is a government-funded program that provides medical benefits to retired members of the Uniformed Services and to spouses and children of active

duty, retired, and deceased members, as well as reservists who were ordered to active duty for thirty days or longer. The program is administered by the Department of Defense and funded by the federal government.

26.

The Civilian Health and Medical Program of the Veterans Administration ("CHAMPVA") provides similar benefits for spouses and children of veterans who are entitled to VA permanent and total disability benefits and to widows and children of veterans who died of service-related disabilities. The program is administered by the Department of Defense and funded by the federal government.

FACTUAL ALLEGATIONS

27.

When Relator was finishing his research during his pursuit of his master's degree in 1998, he discovered that there was an employment opening for a blood bank manager at Defendant Brookwood Hospital. He later applied for the position and was hired to commence work on September 28, 1998.

28.

As stated above, LabCorp was Relator's employer from the inception of his hire through April 2004, at which time Relator left LabCorp to pursue a career in the blood banking reagent production business in Georgia.

29.

LabCorp subcontracted with Brookwood Hospital and Tenet to operate several different laboratories. One of the laboratories operated by LabCorp for Brookwood Hospital and Tenet was the Blood Bank laboratory.

30.

While acting as manager of the Blood Bank, Relator's responsibilities involved the monitoring of the daily operation of his department and its staff members. He also was charged with monitoring the turn around time for patient tests results.

31.

During Relator's employment, he was in frequent contact with Margie Osborne. Ms. Osborne was a Tenet employee who worked in the Brookwood Hospital Finance Department. Relator believes that Ms. Osborne periodically performed audit functions for Tenet.

32.

Ms. Osborne made inquiries of Relator from time to time with regard to minor billing questions which involved the Blood Bank. At times she would communicate with Relator telephonically and, at other times, she would communicate with Relator via e-mail.

33.

When a billing discrepancy was detected by Defendant Tenet's finance or billing departments regarding the Blood Bank and brought to Relator's attention, he was asked to prepare a written response and a corrective action plan.

34.

At times the e-mail communications from Ms. Osborne were brought to Relator's attention through Rita Kelly. Ms. Kelly was the lab manager for LabCorp and she oversaw numerous different laboratory departments therein, including the Blood Bank.

35.

For example, early in April 2000, Rita Kelly contacted Relator with regard to a billing discrepancy.

36.

Ms. Kelly told Relator to contact Margie Osborne with regard to some overcharges that became apparent during a chart audit for the month of March 2000.

37.

Relator then contacted Ms. Osborne and she directed Relator to the Tenet Finance Department to investigate the billings for patients who had been pulled for review and/or audit.

38.

Relator made copies of the original billing records as requested and proceeded to investigate the problem.

39.

As a part of his investigation, Relator compared the records generated by the Blood Bank for the patients in question against audit documents that he had copied from the Tenet billing department.

40.

Relator uncovered two serious billing problems. The first problem resulted in a double billing whereby patients were billed for red blood cell components allegedly received during a transfusion that were never provided to the patient. The second problem dealt with the improper billing of expensive and non-necessary filters that were never used

41.

In order to understand the first problem, it is very important to understand the difference between two different types of blood products. Many patients received a transfusion of regular, non-filtered red cells ("Standard RBCs") from the Blood Bank. Other patients, such as cancer patients, required a different type of transfusion of red blood cells that were free of white cells or leukocytes ("Depleted RBCs"). Patients receiving Depleted RBCs received a blood product

that had already been filtered carefully and the white cells had been removed. The Depleted RBCs did not have the white cells which can be contaminated with bacteria and pose problems for patients with compromised immune systems.

42.

Relator discovered a systemic billing error that had been occurring on a daily basis from January 1997 through April 2000. Specifically, when Depleted RBCs were billed from the Blood Bank computer system to the Tenet hospital billing interfaced system ("PATCOM"), a billing error occurred. Tenet provided the interfacing software used by the Blood Bank and Brookwood Hospital.

43.

In every instance when Depleted RBCs were transfused, the patients were also billed for Standard RBCs that were not provided to the patient. This resulted in a double billing because the patients did not receive both Depleted RBCs and Standard RBCs.

44.

By way of example, business records generated by Defendant Brookwood Medical Center for Defendant Tenet are attached hereto as Exhibit 1.

45.

Within Exhibit 1, you will see that patient account no. 008329666 was billed for 19 Depleted RBC transfusions. Additionally, Exhibit 1 similarly reflects that the same patient received 21 units of Standard RBCs.

46.

As stated above, the patient did not and could not receive both Depleted RBCs and Standard RBCs. The patient was only receiving Depleted RBCs but a bill was simultaneously being generated for Standard RBCs which were not transfused.

47.

Therefore, the patient was overcharged as a result of the billing system defect(s) existing in the Tenet billing system operated and utilized by Defendants Brookwood Hospital and Tenet.

48.

On page 3 of Exhibit 1, the second problem detected by Relator is also evident. Specifically, you will see that the same patient was billed for 20 “leukocyte filters.” Leukocyte filters are not needed when Depleted RBCs are used because the blood product has already been filtered and the white cells have already been removed.

49.

These leukocyte filters are very expensive and totally superfluous for purposes of transfusing Depleted RBCs. Leukocyte filters would only be useful if Standard RBCs were being transfused.

50.

When a patient is receiving Depleted RBCs, a simple and inexpensive Y-set filter ("Y filter") should be utilized. The leukocyte filters were not used but a billing for these filters was generated every time Depleted RBCs were transfused. The leukocyte filter was billed at \$165.70 per filter. The "Y filters" are very inexpensive and a case of 50 can be purchased for \$77.88. This equates to approximately \$1.56 per filter.

51.

In summary, the patient account that was audited by Relator reflected an improper billing of Standard RBCs (when only Depleted RBCs were used) and an overbilling problem wherein expensive leukocyte filters were charged and billed but not necessary or provided to the patient. In reality, the patient actually needed and used the inexpensive "Y filters."

52.

Upon further investigation, the Relator found out that these two problems were not confined to any particular patient as they applied to all patient billings

emanating from the Blood Bank from January 1997 through April 2000. In that period, 4,035 units of Standard RBCs billed at \$156.80 each were billed at \$165.00 per filter but not provided and 26,649 leukocyte filters were billed but not provided. These billing errors total millions of dollars in overcharges for that period.

53.

Many Medicare, Medicaid, CHAMPUS, and CHAMPVA patients were treated at the Blood Bank managed by LabCorp pursuant to its contract with Brookwood Hospital and Tenet during the period in question.

54.

Relator has it, upon information and belief, that over 40 percent of all such patients seen at the Blood Bank during that period were Medicare, Medicaid, CHAMPUS or CHAMPVA beneficiaries.

55.

Accordingly, these billing errors and charges for products not appropriately provided or billed to federal beneficiaries resulted in hundreds of thousands of dollars of overcharges to the aforementioned federally-funded programs (See Exhibit 2 attached here for monthly billing records related to the period at issue).

56.

After Relator discovered the two systemic billing errors referenced above, he communicated the problem to the Tenet and Brookwood Hospital Finance Department through Glen Salee. Mr. Salee was a senior executive within the Finance Department at Brookwood Hospital. Relator believes that Mr. Salee was a Tenet employee.

57.

Relator also completed a "Chart Audit Action Plan" and provided it to Brookwood Hospital. See Exhibit 3 attached hereto.

58.

The problem was also communicated to the Brookwood Hospital Information System Administrator, Mr. Manuel Price. Relator believes that Mr. Price was a Tenet employee.

59.

Relator was told by Messrs. Salee and Price that the problem would be "fixed" immediately in order to cure the double-billing problem that Relator had uncovered relating to Standard RBCs that were billed but never provided.

60.

Relator also discussed the improper coding used for the "Y filter" with Mr. Salee as well. Inexpensive "Y filters" were being used, but the patients were being

billed for expensive leukocyte filters that were not being used. The overcharges were caused by a coding error that occurred in each instance when Depleted RBCs were transferred. When the Blood Bank entered the code for a Depleted RBC, the Tenet billing system automatically added a leukocyte filter charge to the bill.

61.

Also, Relator was told that Brookwood Hospital did not wish to bill at all from that time forward for “Y filters” because these filters were already paid for as part of the blood administration charges that were already being billed to the patient. Consequently, Relator dictated a memo to his staff that directed them to stop any future billing of the “Y filters.” See Exhibit 4 attached hereto.

62.

In addition to Messrs. Salee and Price referenced above, Relator’s laboratory director, Rita Kelly, was also made aware of the billing errors uncovered by Relator.

63.

Additionally, the Blood Bank computer coordinator (David Murray) and laboratory information systems supervisor (Kenny Smith) were aware of Relator’s findings. Messrs. Murray and Smith were LabCorp employees.

64.

Relator was told at that time that Glen Salee, Rita Kelly, and Kenny Smith were members of the Brookwood Hospital “compliance team” and that they held regularly scheduled meetings. Mr. Salee assured Relator, after Relator’s investigation ended on or about April 17, 2000, that both problems would be conveyed to the Brookwood Hospital Compliance Committee, as well as to Tenet’s corporate offices for action.

65.

Relator remained the Blood Bank manager for approximately four more years. The billing codes used by the Blood Bank were changed so that the leukocyte filters were no longer erroneously being coded as being provided to patients who actually used “Y” filters as a part of the Depleted RBC transfusion process after April 2000.

66.

However, because Relator did not have access to the internal billing and financial records maintained by Brookwood Hospital and Tenet for the patients seen in the Blood Bank, he has not been able to determine if the double-billing practices were corrected. Over the next four years, he heard nothing about any curative action from any of the Defendants despite his requests for information.

67.

Relator has it, upon information and belief, that Defendants did not disburse to the United States or report the double-billing errors or the billing errors for the leukocyte filters which were billed but not provided to Medicare, Medicaid, CHAMPUS and CHAMPVA beneficiaries.

68.

After Relator uncovered and reported the improper billing practices referenced above, he was left out of further billing audits and investigations. When Relator asked if the billing improprieties had been addressed, he was told by Mr. Salee that "Our corporate office will handle it."

COUNT I

Violation of False Claims Act

31 U.S.C. § 3729-33

69.

Paragraphs 1 through 68 are incorporated into Count I as if fully set forth herein.

70.

This is a civil action brought by Relator on behalf of the United States against the Defendants under the Federal False Claims Act, 31 U.S.C. § 3729-33.

71.

The Defendants knowingly or reckless disregarded or in deliberate ignorance of the truth or the falsity of the information involved, presented or caused to be presented, false or fraudulent claims for payment to federally-funded health insurance programs, in violation of, inter alia 31 U.S.C. § 3729(a)(1).

72.

Further, the Defendants in reckless disregard or deliberate ignorance of the truth or the falsity of the information involved, made, used, caused to be made, or caused to be used, false or fraudulent records and statements to get false or fraudulent claims paid or approved, in violation of, inter alia 31 U.S.C. § 3729(a)(2).

73.

The United States of America, unaware of the falsity of the claims and/or statements made or caused to be made by the Defendants, and in reliance on the accuracy of these claims and/or statements, paid for blood transfusion services and products provided to individuals insured by federally-funded health insurance programs, including Medicare and Medicaid. Had the United States known that the bills presented by Defendants for payment were false and misleading, payment would have not have been made for such claims.

74.

As a result of Defendants' actions, the United States has been severely damaged.

COUNT II

Conspiracy to Violate the False Claims Act

31 U.S.C. § 3729(a)(3)

75.

Paragraphs 1 through 74 are incorporated into Count II as if fully set forth herein.

76.

The Defendants conspired with one another to get false and fraudulent claims allowed and paid by the United States.

77.

The Defendants conspired together and later withheld information specifically known to Defendants regarding the fraudulent billing of patients to the United States.

78.

Accordingly, the Defendants acted in a concerted fashion to defraud the United States, and the Defendants acted together in keeping the facts necessary to

investigate the fraud and the damages caused by the fraud away from the United States. Accordingly, the Defendants violated 31 U.S.C. § 3729(a)(3).

79.

As a result of the Defendants' actions, the United States has been severely damaged.

WHEREFORE, Relator prays for judgment against Defendants as follows:

(a) That Defendants be ordered to cease and desist from submitting and/or causing the submission of additional false claims or otherwise violating 31 U.S.C. § 3729-33;

(b) That judgment be entered in favor of the United States and Relator and against the Defendants in the amount of each and every false or fraudulent claim multiplied as provided by 31 U.S.C. § 3729(a), plus a civil penalty of not less than Five Thousand Five Hundred and No/100 (\$5,500.00) Dollars, and no more than Eleven Thousand and No/100 (\$11,000.00) Dollars per claim, as provided by 31 U.S.C. § 3729(a), to the extent such multiplied penalties shall fairly compensate the United States of America for losses resulting from the various schemes undertaken by Defendants, together with penalties for specific claims to be identified at trial after full discovery; and

(c) That Relator be awarded the maximum amount permissible according to 31 U.S.C. § 3730(d); and

(d) That judgment be granted for the United States of America and Relator and against Defendants for any costs including, but not limited to, court costs, expert fees, and all attorneys' fees incurred by Relator in the prosecution of this suit; and

(e) That the United States and Relator be granted such other and further relief as the Court deems just and proper.


This 10TH day of November, 2004.

Respectfully submitted,

HARMON, SMITH, BRIDGES
& WILBANKS



Marlan B. Wilbanks
Georgia Bar No. 758223



Tyrone M. Bridges
Georgia Bar No. 081500

Attorneys for Relator Emad Balkash

1795 Peachtree Street
Suite 350
Atlanta, Georgia 30309-2339
Telephone (404) 881-1200
Facsimile (404) 881-8523

Brookwood Medical Center

2010 Brookwood Medical Center Drive, Birmingham, AL 35209-0000

Detail Line Work Sheet Sorted Alphabetically by Charge

Patient Name : Brock, James L
 Account No. : 008329666
 Med Record No: 0608481
 Auditor : Osborn, Marjorie


Page 1
 Admission : 02/16/00
 Discharge : 03/15/00
 Audit Date: 03/20/00

| Charge Code | Service Description | Service Date | Units Billed | Amount Billed | Ord MD Code | Over Billed | Under Billed |
|-------------------------------------|---------------------------|--------------|--------------|---------------|-------------|-------------|--------------|
| Blood & Blood Derivative | | | | | | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 02/17/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 02/18/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 02/19/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 02/20/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 02/20/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 02/22/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 02/24/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 02/24/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 02/24/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 02/26/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 02/26/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 02/28/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 02/28/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 02/28/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 03/02/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 03/04/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 03/08/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 03/08/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 03/08/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 03/09/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 03/09/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 03/10/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 03/11/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 03/11/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 03/13/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 03/13/00 | 1 | 35.20 | 0 | | |
| 40800583 | IRRADIATED DIRECTED DONAR | 03/15/00 | 1 | 35.20 | 0 | | |
| | | | | 950.40 | | 2 | 1 |
| 40800112 | LEUKOCYTE-DEPLETED RBC'S | 02/19/00 | 1 | 231.00 | 0 | | |
| 40800112 | LEUKOCYTE-DEPLETED RBC'S | 02/21/00 | 1 | 231.00 | 0 | | |
| 40800112 | LEUKOCYTE-DEPLETED RBC'S | 02/22/00 | 1 | 231.00 | 0 | | |
| 40800112 | LEUKOCYTE-DEPLETED RBC'S | 02/24/00 | 1 | 231.00 | 0 | | |
| 40800112 | LEUKOCYTE-DEPLETED RBC'S | 02/24/00 | 1 | 231.00 | 0 | | |
| 40800112 | LEUKOCYTE-DEPLETED RBC'S | 02/26/00 | 1 | 231.00 | 0 | | |
| 40800112 | LEUKOCYTE-DEPLETED RBC'S | 02/28/00 | 1 | 231.00 | 0 | | |
| 40800112 | LEUKOCYTE-DEPLETED RBC'S | 02/28/00 | 1 | 231.00 | 0 | | |

Prepared using AP Plus

Worksheet(s) by Department

Day del
 in blood
 2/28/00



Detail Line Work Sheet Sorted Alphabetically by Charge

Patient Name : Brock, James L
 Account No. : 008329666
 Med Record No: 0608481
 Auditor : Osborn, Marjorie

Page 2
 Admission : 02/16/00
 Discharge : 03/15/00
 Audit Date: 03/20/00

| Charge Code | Service Description | Service Date | Units Billed | Amount Billed | Ord MD Code | Over Billed | Under Billed |
|-------------------------------------|--------------------------|--------------|---------------------|---------------|-------------|-----------------|--------------|
| Blood & Blood Derivative | | | | | | | |
| 40800112 | LEUKOCYTE-DEPLETED RBC'S | 03/02/00 | 1 1 ¹ | 231.00 0 | | | |
| 40800112 | LEUKOCYTE-DEPLETED RBC'S | 03/08/00 | 1 1 ⁷ | 231.00 0 | | | |
| 40800112 | LEUKOCYTE-DEPLETED RBC'S | 03/08/00 | 1 1 ⁷ | 231.00 0 | | | |
| 40800112 | LEUKOCYTE-DEPLETED RBC'S | 03/08/00 | 1 0 | 231.00 0 | | 1 ^{7X} | |
| 40800112 | LEUKOCYTE-DEPLETED RBC'S | 03/09/00 | 1 1 ⁸ | 231.00 0 | | | |
| 40800112 | LEUKOCYTE-DEPLETED RBC'S | 03/09/00 | 1 1 ⁸ | 231.00 0 | | | |
| 40800112 | LEUKOCYTE-DEPLETED RBC'S | 03/10/00 | 1 1 ⁹ | 231.00 0 | | | |
| 40800112 | LEUKOCYTE-DEPLETED RBC'S | 03/11/00 | 1 1 ¹⁰ | 231.00 0 | | | |
| 40800112 | LEUKOCYTE-DEPLETED RBC'S | 03/13/00 | 1 1 ¹⁰ | 231.00 0 | | | |
| 40800112 | LEUKOCYTE-DEPLETED RBC'S | 03/13/00 | 1 1 ¹⁰ | 231.00 0 | | | |
| 40800112 | LEUKOCYTE-DEPLETED RBC'S | 03/15/00 | 1 1 ¹⁴ | 231.00 0 | | | |

17

(15) 19 20 4,389.00 | 1 | 2

| | | | | | | | |
|----------|------------|----------|------------|------------|--|--|--|
| 40800187 | PACKED RBC | 02/17/00 | 1 1-16 ✓ | 156.80 0 | | | |
| 40800187 | PACKED RBC | 02/18/00 | 1 1-17 ✓ | 156.80 0 | | | |
| 40800187 | PACKED RBC | 02/19/00 | 1 1-18 ✓ | 156.80 0 | | | |
| 40800187 | PACKED RBC | 02/20/00 | 1 1-19 ✓ | 156.80 0 | | | |
| 40800187 | PACKED RBC | 02/21/00 | 1 1-20 ✓ | 156.80 0 | | | |
| 40800187 | PACKED RBC | 02/22/00 | 1 1-21 ✓ | 156.80 0 | | | |
| 40800187 | PACKED RBC | 02/24/00 | 1 1-23 ✓ | 156.80 0 | | | |
| 40800187 | PACKED RBC | 02/24/00 | 1 1-23 ✓ | 156.80 0 | | | |
| 40800187 | PACKED RBC | 02/26/00 | 1 1-25 ✓ | 156.80 0 | | | |
| 40800187 | PACKED RBC | 02/28/00 | 1 1-27 ✓ | 156.80 0 | | | |
| 40800187 | PACKED RBC | 02/28/00 | 1 1-27 ✓ | 156.80 0 | | | |
| 40800187 | PACKED RBC | 03/02/00 | 1 1-1 ✓ | 156.80 0 | | | |
| 40800187 | PACKED RBC | 03/08/00 | 1 1-7 ✓ | 156.80 0 | | | |
| 40800187 | PACKED RBC | 03/08/00 | 1 1-7 ✓ | 156.80 0 | | | |
| 40800187 | PACKED RBC | 03/09/00 | 1 1-8 ✓ | 156.80 0 | | | |
| 40800187 | PACKED RBC | 03/09/00 | 1 1-8 ✓ | 156.80 0 | | | |
| 40800187 | PACKED RBC | 03/10/00 | 1 1-9 ✓ | 156.80 0 | | | |
| 40800187 | PACKED RBC | 03/11/00 | 1 1-10 ✓ | 156.80 0 | | | |
| 40800187 | PACKED RBC | 03/13/00 | 1 1-12 ✓ | 156.80 0 | | | |
| 40800187 | PACKED RBC | 03/13/00 | 1 1-12 ✓ | 156.80 0 | | | |
| 40800187 | PACKED RBC | 03/15/00 | 1 1-14 ✓ | 156.80 0 | | | |

21 | 21 3,292.80 |

| | | | | | | | |
|----------|------------------|----------|---------------------|------------|--|--|--|
| 40800203 | PLATELETPHERESIS | 02/26/00 | 1 1 ²⁵ | 880.00 0 | | | |
| 40800203 | PLATELETPHERESIS | 03/04/00 | 1 1 ³ | 880.00 0 | | | |
| 40800203 | PLATELETPHERESIS | 03/08/00 | 1 1 ⁷ | 880.00 0 | | | |
| 40800203 | PLATELETPHERESIS | 03/11/00 | 1 1 ¹⁰ | 880.00 0 | | | |
| 40800203 | PLATELETPHERESIS | 03/15/00 | 1 1 ¹¹ | 880.00 0 | | | |

Detail Line Work Sheet Sorted Alphabetically by Charge

Patient Name : Brock, James L
 Account No. : 008329666
 Med Record No: 0608481
 Auditor : Osborn, Marjorie

Page 8
 Admission : 02/16/00
 Discharge : 03/15/00
 Audit Date: 03/20/00

| Charge Code | Service Description | Service Date | Units Billed | Amount Billed | Ord MD Code | Over Billed | Under Billed |
|-------------------------------------|-------------------------------|--------------|--------------|---------------|-------------|-------------|--------------|
| IV & Irrigating Solution | | | | | | | |
| 50290626 | IV SET EXTENSION 2-Y SITE | 03/14/00 | 2 2 | 127.80 0 | | | |
| | | | 13 13 | 830.70 | | | |
| 50291236 | IV SET IVAC NONFILTER VENTED | 02/16/00 | 1 1 | 78.90 0 | | | |
| 50291236 | IV SET IVAC NONFILTER VENTED | 02/16/00 | 1 1 | 78.90 0 | | | |
| 50291236 | IV SET IVAC NONFILTER VENTED | 02/17/00 | 1 1 | 78.90 0 | | | |
| 50291236 | IV SET IVAC NONFILTER VENTED | 02/18/00 | 1 1 | 78.90 0 | | | |
| 50291236 | IV SET IVAC NONFILTER VENTED | 02/19/00 | 1 1 | 78.90 0 | | | |
| 50291236 | IV SET IVAC NONFILTER VENTED | 02/20/00 | 1 1 | 78.90 0 | | | |
| 50291236 | IV SET IVAC NONFILTER VENTED | 02/21/00 | 1 1 | 78.90 0 | | | |
| 50291236 | IV SET IVAC NONFILTER VENTED | 02/22/00 | 1 1 | 78.90 0 | | | |
| 50291236 | IV SET IVAC NONFILTER VENTED | 02/23/00 | 1 1 | 78.90 0 | | | |
| 50291236 | IV SET IVAC NONFILTER VENTED | 02/25/00 | 1 1 | 78.90 0 | | | |
| 50291236 | IV SET IVAC NONFILTER VENTED | 02/26/00 | 1 1 | 78.90 0 | | | |
| 50291236 | IV SET IVAC NONFILTER VENTED | 02/29/00 | 1 1 | 78.90 0 | | | |
| 50291236 | IV SET IVAC NONFILTER VENTED | 03/01/00 | 1 1 | 78.90 0 | | | |
| 50291236 | IV SET IVAC NONFILTER VENTED | 03/04/00 | 1 1 | 78.90 0 | | | |
| 50291236 | IV SET IVAC NONFILTER VENTED | 03/06/00 | 1 1 | 78.90 0 | | | |
| 50291236 | IV SET IVAC NONFILTER VENTED | 03/07/00 | 1 1 | 78.90 0 | | | |
| 50291236 | IV SET IVAC NONFILTER VENTED | 03/10/00 | 1 1 | 78.90 0 | | | |
| 50291236 | IV SET IVAC NONFILTER VENTED | 03/10/00 | 1 1 | 78.90 0 | | | |
| 50291236 | IV SET IVAC NONFILTER VENTED | 03/11/00 | 1 1 | 78.90 0 | | | |
| 50291236 | IV SET IVAC NONFILTER VENTED | 03/12/00 | 1 1 | 78.90 0 | | | |
| 50291236 | IV SET IVAC NONFILTER VENTED | 03/14/00 | 2 2 | 157.80 0 | | | |
| | | | 22 22 | 1,735.80 | | | |
| 50291608 | IV SET LEUKOCYTE FILTER (RBC) | 02/18/00 | 1 1-19 ✓ | 165.70 0 | | | |
| 50291608 | IV SET LEUKOCYTE FILTER (RBC) | 02/20/00 | 1 1 ✓ | 165.70 0 | | | |
| 50291608 | IV SET LEUKOCYTE FILTER (RBC) | 02/21/00 | 1 0 | 165.70 0 | | | |
| 50291608 | IV SET LEUKOCYTE FILTER (RBC) | 02/23/00 | 1 1 ✓ | 165.70 0 | | | |
| 50291608 | IV SET LEUKOCYTE FILTER (RBC) | 02/23/00 | 1 1 ✓ | 165.70 0 | | | |
| 50291608 | IV SET LEUKOCYTE FILTER (RBC) | 02/25/00 | 1 1 ✓ | 165.70 0 | | | |
| 50291608 | IV SET LEUKOCYTE FILTER (RBC) | 02/27/00 | 1 1 ✓ | 165.70 0 | | | |
| 50291608 | IV SET LEUKOCYTE FILTER (RBC) | 03/01/00 | 1 13 ✓ | 165.70 0 | | | |
| 50291608 | IV SET LEUKOCYTE FILTER (RBC) | 03/03/00 | 1 1 ✓ | 165.70 0 | | | |
| 50291608 | IV SET LEUKOCYTE FILTER (RBC) | 03/07/00 | 1 0 | 165.70 0 | | | |
| 50291608 | IV SET LEUKOCYTE FILTER (RBC) | 03/07/00 | 1 1 ✓ | 165.70 0 | | | |
| 50291608 | IV SET LEUKOCYTE FILTER (RBC) | 03/07/00 | 1 0 | 165.70 0 | | | |
| 50291608 | IV SET LEUKOCYTE FILTER (RBC) | 03/08/00 | 1 1 ✓ | 165.70 0 | | | |
| 50291608 | IV SET LEUKOCYTE FILTER (RBC) | 03/08/00 | 1 0 | 165.70 0 | | | |
| 50291608 | IV SET LEUKOCYTE FILTER (RBC) | 03/09/00 | 1 1 ✓ | 165.70 0 | | | |

Detail Line Work Sheet Sorted Alphabetically by Charge

Patient Name : Brock, James L
 Account No. : 008329666
 Med Record No: 0608481
 Auditor : Osborn, Marjorie

Page 9
 Admission : 02/16/00
 Discharge : 03/15/00
 Audit Date: 03/20/00

| Charge Code | Service Description | Service Date | Units Billed | Amount Billed | Ord MD Code | Over Billed | Under Billed |
|-------------------------------------|-------------------------------|--------------|--------------|------------------|-------------|-------------|--------------|
| IV & Irrigating Solution | | | | | | | |
| 50291608 | IV SET LEUKOCYTE FILTER (RBC) | 03/10/00 | 1 1 | 165.70 0 | | | |
| 50291608 | IV SET LEUKOCYTE FILTER (RBC) | 03/10/00 | 1 1 | 165.70 0 | | | |
| 50291608 | IV SET LEUKOCYTE FILTER (RBC) | 03/12/00 | 1 1 | 165.70 0 | | | |
| 50291608 | IV SET LEUKOCYTE FILTER (RBC) | 03/12/00 | 1 1 | 165.70 0 | | | |
| 50291608 | IV SET LEUKOCYTE FILTER (RBC) | 03/15/00 | 1 1 | 165.70 0 | | | |
| | | | | 20 16 3,314.00 | | 4 | |
| 50290766 | IV SET PLATELET CONC INFUSION | 02/19/00 | 1 0 | 369.50 0 | | 19 | 3/4 7 10 |
| 50290766 | IV SET PLATELET CONC INFUSION | 02/25/00 | 1 1 | 369.50 0 | | | 1+1+1 |
| 50290766 | IV SET PLATELET CONC INFUSION | 03/14/00 | 1 1 | 369.50 0 | | | |
| | | | | 3 5 1,108.50 | | 1 | 3 |
| 50291855 | IV SET STARTER W/O CATH | 02/16/00 | 1 1 | 23.40 0 | | | |
| 50291855 | IV SET STARTER W/O CATH | 02/18/00 | 1 1 | 23.40 0 | | | |
| 50291855 | IV SET STARTER W/O CATH | 03/02/00 | 1 1 | 23.40 0 | | | |
| 50291855 | IV SET STARTER W/O CATH | 03/03/00 | 1 1 | 23.40 0 | | | |
| 50291855 | IV SET STARTER W/O CATH | 03/05/00 | 2 2 | 46.80 0 | | | |
| | | | | 6 6 140.40 | | | |
| 50290675 | IV SET SYRINGE PUMP W/NEEDLE | 02/20/00 | 1 1 | 63.90 0 | | | |
| 50290675 | IV SET SYRINGE PUMP W/NEEDLE | 02/21/00 | 1 1 | 63.90 0 | | | |
| 50290675 | IV SET SYRINGE PUMP W/NEEDLE | 02/23/00 | 1 1 | 63.90 0 | | | |
| 50290675 | IV SET SYRINGE PUMP W/NEEDLE | 02/25/00 | 1 1 | 63.90 0 | | | |
| 50290675 | IV SET SYRINGE PUMP W/NEEDLE | 02/27/00 | 1 1 | 63.90 0 | | | |
| 50290675 | IV SET SYRINGE PUMP W/NEEDLE | 03/02/00 | 1 1 | 63.90 0 | | | |
| 50290675 | IV SET SYRINGE PUMP W/NEEDLE | 03/02/00 | 1 1 | 63.90 0 | | | |
| 50290675 | IV SET SYRINGE PUMP W/NEEDLE | 03/04/00 | 1 1 | 63.90 0 | | | |
| 50290675 | IV SET SYRINGE PUMP W/NEEDLE | 03/07/00 | 1 1 | 63.90 0 | | | |
| 50290675 | IV SET SYRINGE PUMP W/NEEDLE | 03/07/00 | 1 1 | 63.90 0 | | | |
| 50290675 | IV SET SYRINGE PUMP W/NEEDLE | 03/08/00 | 1 1 | 63.90 0 | | | |
| 50290675 | IV SET SYRINGE PUMP W/NEEDLE | 03/09/00 | 1 1 | 63.90 0 | | | |
| 50290675 | IV SET SYRINGE PUMP W/NEEDLE | 03/11/00 | 1 1 | 63.90 0 | | | |
| 50290675 | IV SET SYRINGE PUMP W/NEEDLE | 03/12/00 | 1 1 | 63.90 0 | | | |
| 50290675 | IV SET SYRINGE PUMP W/NEEDLE | 03/14/00 | 1 1 | 63.90 0 | | | |
| | | | | 15 15 958.50 | | | |
| 50271451 | IV SOLN 5 - 500ML | 02/21/00 | 1 | 106.40 0 | | | |

BLOOD PRODUCT USAGE REPORT

| | All Products | Apr-00 Cellular | % of Total | All Products | May-00 Cellular | % of Total | All Products | Jun-00 Cellular | % of Total |
|--|--------------|--------------------|------------|--------------|--------------------|------------|--------------|--------------------|------------|
| Total Number of Crossmatches | | 778 | | | 812 | | | 699 | |
| Total Number of Transfusions | 966 | 478 | 49.48 | 1265 | 561 | 44.35 | 1107 | 420 | 37.94 |
| Total Number of Used Crossmatches | | 468 | | | 559 | | | 419 | |
| Percent of Used Crossmatches | | 60.15 | | | 68.84 | | | 59.94 | |
| Total Number of Patients Crossmatched | | 214 | | | 216 | | | 205 | |
| Total Number of Patients Transfused | 189 | 152 | 80.42 | 210 | 168 | 80 | 187 | 141 | 75.4 |
| Average Number of Transfusions/Patient | 5.1 | 3.1 | | 6 | 3.3 | | 5.9 | 3 | |
| Total Number of Single Unit Transfusions | 42 | 16 | 38.1 | 43 | 14 | 32.56 | 46 | 15 | 32.61 |
| C/T Ratio | | 1.7:1 | | | 1.5:1 | | | 1.7:1 | |
| Total Number of Patients Tested | | 891 | | | 951 | | | 913 | |
| Products Transfused: | | | | | | | | | |
| Red Blood Cells | | 307 | | | 371 | | | 304 | |
| Irradiated Red Blood Cells | | 1 | | | 1 | | | 0 | |
| Leuko-depleted Red Blood Cells | | 144 | | | 160 | | | 101 | |
| Irrad. Leukodep. Red Blood Cells | | 11 | | | 10 | | | 8 | |
| Pedi Leuko-depleted Red Blood Cells | | 10 | | | 1 | | | 1 | |
| Split Red Cell (adult) | | 0 | | | 0 | | | 0 | |
| Washed Red Blood Cells | | 2 | | | 0 | | | 0 | |
| Deglycerolized Red Blood Cells | | 0 | | | 0 | | | 0 | |
| Apheresed Platelets | | 0 | | | 0 | | | 0 | |
| Leuko-depleted Apheresed Platelets | | 57 | | | 58 | | | 21 | |
| Irradiated Apheresed Platelets | | 10 | | | 8 | | | 9 | |
| Random platelets | | 7 | | | 0 | | | 0 | |
| Irradiated Random Platelets | | 0 | | | 0 | | | 0 | |
| Pediatric Platelets | | 2 | | | 0 | | | 1 | |
| Fresh Frozen Plasma | | 322 | | | 599 | | | 616 | |
| Jumbo Fresh Frozen Plasma | | 0 | | | 0 | | | 0 | |
| Pediatric Fresh Frozen Plasma | | 5 | | | 0 | | | 0 | |
| Cryoprecipitate | | 58 | | | 8 | | | 10 | |
| Pediatric Cryoprecipitate | | 0 | | | 0 | | | 0 | |
| Rh Immune Globulin-full dose | | 27 | | | 27 | | | 23 | |
| Rh Immune Globulin-mini dose | | 0 | | | 3 | | | 6 | |
| Autologous Units Transfused: | | | | | | | | | |
| | | 0 | | | 4 | | | 6 | |
| Directed Donor Units Transfused: | | | | | | | | | |
| | | 2 | | | 13 | | | 0 | |

BLOOD PRODUCT USAGE REPORT

| | All Products | Jul-99 Cellular | % of Total | All Products | Aug-99 Cellular | % of Total | All Products | Sep-99 Cellular | % of Total |
|---|--------------|--------------------|------------|--------------|--------------------|------------|--------------|--------------------|------------|
| Total Number of Crossmatches | | 763 | | | 719 | | | 761 | |
| Total Number of Transfusions | 764 | 519 | 67.93 | 751 | 467 | 62.18 | 782 | 531 | 67.9 |
| Total Number of Used Crossmatched | | 510 | | | 451 | | | 518 | |
| Percent of Used Crossmatches | | 66.84 | | | 62.73 | | | 68.07 | |
| Total Number of Patients Crossmatched | 225 | | | 194 | | | 195 | | |
| Total Number of Patients Transfused | 225 | 172 | 76.44 | 184 | 146 | 79.35 | 194 | 158 | 81.44 |
| Average Number of Transfusions/Patient | 3.4 | 3 | 4.1 | 4.1 | 3.2 | | 4 | 3.4 | |
| Total Number of Single Unit Transfusions | 58 | 15 | 25.86 | 44 | 15 | 34.09 | 40 | 12 | 30 |
| C/T Ratio | | 15:1 | | | 16:1 | | | 15:1 | |
| Total Number of Patients Tested | | 992 | | | 998 | | | 906 | |
| Products Transfused: | | | | | | | | | |
| Red Blood Cells | 352 | | | | 348 | | | 422 | |
| Irradiated Red Blood Cells | 1 | | | | 5 | | | 6 | |
| Leuko-depleted Red Blood Cells | 146 | | | | 85 | | | 86 | |
| Pedi Leuko-depleted Red Blood Cells | 8 | | | | 15 | | | 13 | |
| Split Red Cell (adult) | 1 | | | | 0 | | | 0 | |
| Washed Red Blood Cells | 0 | | | | 0 | | | 0 | |
| Deglycerolized Red Blood Cells | 0 | | | | 0 | | | 0 | |
| Apheresed Platelets | 38 | | | | 45 | | | 39 | |
| Leuko-depleted Apheresed Platelets | 0 | | | | 0 | | | 0 | |
| Irradiated Apheresed Platelets | 3 | | | | 7 | | | 10 | |
| Random platelets | 8 | | | | 8 | | | 0 | |
| Irradiated Random Platelets | 0 | | | | 0 | | | 0 | |
| Pediatric Platelets | 0 | | | | 0 | | | 0 | |
| Fresh Frozen Plasma | 147 | | | | 187 | | | 133 | |
| Jumbo Fresh Frozen Plasma | 0 | | | | 0 | | | 0 | |
| Pediatric Fresh Frozen Plasma | 0 | | | | 0 | | | 0 | |
| Cryoprecipitate | 10 | | | | 10 | | | 39 | |
| Pediatric Cryoprecipitate | 0 | | | | 0 | | | 0 | |
| Rh Immune Globulin-full dose | 34 | | | | 27 | | | 29 | |
| Rh Immune Globulin-mini dose | 5 | | | | 0 | | | 1 | |
| Autologous Units Transfused: | 4 | | | | 2 | | | 4 | |
| Directed Donor Units Transfused: | 7 | | | | 12 | | | 0 | |
| *all apheresed platelets received from ACBB are leuko-reduced | | | | | | | | | |

BLOOD PRODUCT USAGE REPORT

| | All Products | Oct-99 Cellular | % of Total | All Products | Nov-99 Cellular | % of Total | All Products | Dec-99 Cellular | % of Total |
|---|--------------|--------------------|------------|--------------|--------------------|------------|--------------|--------------------|------------|
| Total Number of Crossmatches | | 713 | | | 908 | | | 705 | |
| Total Number of Transfusions | 791 | 505 | 63.8 | 903 | 601 | 66.6 | 945 | 426 | 45.1 |
| Total Number of Used Crossmatched | | 471 | | | 578 | | | 401 | |
| Percent of Used Crossmatches | | 66.1 | | | 63.7 | | | 56.9 | |
| Total Number of Patients Crossmatched | 193 | | | 237 | | | 208 | | |
| Total Number of Patients Transfused | 205 | 151 | 73.7 | 206 | 167 | 81.1 | 193 | 146 | 75.7 |
| Average Number of Transfusions/Patient | 3.9 | 3.3 | 3.3 | 4.4 | 3.6 | | 4.9 | 2.9 | |
| Total Number of Single Unit Transfusions | 51 | 12 | 23.5 | 33 | 9 | 27.3 | 53 | 18 | 34 |
| C/T Ratio | | 1.5:1 | | | 1.6:1 | | | 1.8:1 | |
| Total Number of Patients Tested | | 907 | | | 900 | | | 867 | |
| Products Transfused: | | | | | | | | | |
| Red Blood Cells | | 361 | | | 428 | | | 292 | |
| Irradiated Red Blood Cells | | 0 | | | 4 | | | 2 | |
| Leuko-depleted Red Blood Cells | | 103 | | | 137 | | | 100 | |
| Pedi Leuko-depleted Red Blood Cells | | 34 | | | 21 | | | 25 | |
| Split Red Cell (adult) | | 1 | | | 0 | | | 0 | |
| Washed Red Blood Cells | | 0 | | | 1 | | | 0 | |
| Deglycerolized Red Blood Cells | | 0 | | | 0 | | | 4 | |
| Apheresed Platelets | | 44 | | | 51 | | | 42 | |
| Leuko-depleted Apheresed Platelets | | 0 | | | 0 | | | 0 | |
| Irradiated Apheresed Platelets | | 4 | | | 15 | | | 5 | |
| Random platelets | | 0 | | | 0 | | | 0 | |
| Irradiated Random Platelets | | 0 | | | 0 | | | 0 | |
| Pediatric Platelets | | 17 | | | 1 | | | 5 | |
| Fresh Frozen Plasma | | 161 | | | 183 | | | 387 | |
| Jumbo Fresh Frozen Plasma | | 0 | | | 0 | | | 0 | |
| Pediatric Fresh Frozen Plasma | | 3 | | | 0 | | | 5 | |
| Cryoprecipitate | | 22 | | | 24 | | | 40 | |
| Pediatric Cryoprecipitate | | 0 | | | 0 | | | 0 | |
| Rh Immune Globulin-full dose | | 34 | | | 26 | | | 33 | |
| Rh Immune Globulin-mini dose | | 1 | | | 1 | | | 2 | |
| Autologous Units Transfused: | | | | | | | | | |
| | | 4 | | | 7 | | | 3 | |
| Directed Donor Units Transfused: | | | | | | | | | |
| | | 2 | | | 3 | | | 0 | |
| *all apheresed platelets received from ACBB are leuko-reduced | | | | | | | | | |

BLOOD PRODUCT USAGE REPORT

| | All Products | Jan-00 Cellular | % of Total | All Product | Feb-00 Cellular | % of Total | All Products | Mar-00 Cellular | % of Total |
|--|--------------|--------------------|------------|-------------|--------------------|------------|--------------|--------------------|------------|
| total Number of Crossmatches | | 734 | | | 751 | | | 837 | |
| total Number of Transfusions | 732 | 479 | 65.4 | 1030 | 464 | 45.1 | 894 | 575 | 64.32 |
| total Number of Used Crossmatches | | 469 | | | 454 | | | 548 | |
| percent of Used Crossmatches | | 63.9 | | | 60.5 | | | 65.47 | |
| total Number of Patients Crossmatched | 191 | | | 202 | | | | 194 | |
| total Number of Patients Transfused | 182 | 141 | 77.5 | 190 | 148 | 77.9 | 186 | 146 | 78.49 |
| average Number of Transfusions/Patient | 4 | 3.4 | | 5.4 | 3.1 | | 4.8 | 3.9 | |
| total Number of Single Unit Transfusions | 37 | 7 | 18.9 | 40 | 13 | 27.1 | 43 | 12 | 27.91 |
| W/T Ratio | | 1.6:1 | | | 1.6:1 | | | 1.5:1 | |
| total Number of Patients Tested | | 914 | | | 908 | | | 934 | |
| Products Transfused: | | | | | | | | | |
| Red Blood Cells | | 328 | | | 308 | | | 371 | |
| irradiated Red Blood Cells | | 10 | | | 9 | | | 6 | |
| euko-depleted Red Blood Cells | | 115 | | | 115 | | | 132 | |
| irrad. Leukodep. Red Blood Cells | | 6 | | | 11 | | | 26 | |
| Pedi Leuko-depleted Red Blood Cells | | 10 | | | 10 | | | 6 | |
| Split Red Cell (adult) | | 0 | | | 1 | | | 0 | |
| Washed Red Blood Cells | | 0 | | | 0 | | | 0 | |
| Deglycerolized Red Blood Cells | | 0 | | | 0 | | | 0 | |
| Apheresed Platelets | | 35 | | | 55 | | | 0 | |
| euko-depleted Apheresed Platelets | | 0 | | | 0 | | | 102 | |
| irradiated Apheresed Platelets | | 7 | | | 2 | | | 16 | |
| Random platelets | | 0 | | | 0 | | | 0 | |
| irradiated Random Platelets | | 0 | | | 0 | | | 0 | |
| Pediatric Platelets | | 3 | | | 0 | | | 3 | |
| Fresh Frozen Plasma | | 145 | | | 448 | | | 158 | |
| Jumbo Fresh Frozen Plasma | | 0 | | | 0 | | | 0 | |
| Pediatric Fresh Frozen Plasma | | 2 | | | 0 | | | 0 | |
| Cryoprecipitate | | 30 | | | 28 | | | 13 | |
| Pediatric Cryoprecipitate | | 0 | | | 0 | | | 0 | |
| Rh Immune Globulin-full dose | | 29 | | | 32 | | | 24 | |
| Rh Immune Globulin-mini dose | | 2 | | | 1 | | | 3 | |
| Autologous Units Transfused: | | 8 | | | 5 | | | 5 | |
| Directed Donor Units Transfused: | | 2 | | | 5 | | | 9 | |

BLOOD PRODUCT USAGE REPORT

| | All Products | Jul-00 | % of Total | All Products | Aug-00 | % of Total | All Products | Sep-00 | % of Total |
|--|--------------|--------|------------|--------------|--------|------------|--------------|--------|------------|
| | Cellular | | | Cellular | | | Cellular | | |
| Total Number of Crossmatches | | 681 | | 737 | | | 565 | | |
| Total Number of Transfusions | 777 | 441 | 56.8 | 671 | 441 | 65.7 | 424 | 680 | 64.2 |
| Total Number of Used Crossmatched | | 425 | | 432 | | | 377 | | |
| Percent of Used Crossmatches | | 62.4 | | 58.6 | | | 66.7 | | |
| Total Number of Patients Crossmatched | | 200 | | 209 | | | 171 | | |
| Total Number of Patients Transfused | 180 | 148 | 82.2 | 188 | 147 | 78.2 | 137 | 193 | 71 |
| Average Number of Transfusions/Patient | 4.3 | 3 | | 3.6 | 3 | | 3.1 | 3.4 | |
| Total Number of Single Unit Transfusions | 38 | 12 | 31.6 | 44 | 14 | 31.8 | 12 | 55 | 21.8 |
| WT Ratio | | 1.6 | | 1.7:1 | | | 1.5:1 | | |
| Total Number of Patients Tested | | 917 | | 958 | | | 1001 | | |
| Products Transfused: | | | | | | | | | |
| Red Blood Cells | | 321 | | 317 | | | 264 | | |
| Irradiated Red Blood Cells | | 0 | | 0 | | | 0 | | |
| Leuko-depleted Red Blood Cells | | 85 | | 93 | | | 102 | | |
| Irrad. Leukodep. Red Blood Cells | | 11 | | 15 | | | 0 | | |
| Pedi Leuko-depleted Red Blood Cells | | 16 | | 9 | | | 47 | | |
| Split Red Cell (adult) | | 1 | | 0 | | | 0 | | |
| Washed Red Blood Cells | | 0 | | 0 | | | 0 | | |
| Deglycerolized Red Blood Cells | | 0 | | 0 | | | 0 | | |
| Apheresed Platelets | | 0 | | 0 | | | 0 | | |
| Leuko-depleted Apheresed Platelets | | 34 | | 25 | | | 32 | | |
| Irradiated Apheresed Platelets | | 7 | | 7 | | | 0 | | |
| Random platelets | | 0 | | 0 | | | 0 | | |
| Irradiated Random Platelets | | 0 | | 0 | | | 0 | | |
| Pediatric Platelets | | 2 | | 0 | | | 18 | | |
| Fresh Frozen Plasma | | 253 | | 167 | | | 127 | | |
| Jumbo Fresh Frozen Plasma | | 0 | | 0 | | | 0 | | |
| Pediatric Fresh Frozen Plasma | | 1 | | 0 | | | 17 | | |
| Cryoprecipitate | | 12 | | 0 | | | 0 | | |
| Pediatric Cryoprecipitate | | 0 | | 0 | | | 0 | | |
| Rh Immune Globulin-full dose | | 23 | | 27 | | | 41 | | |
| Rh Immune Globulin-mini dose | | 4 | | 2 | | | 1 | | |
| Autologous Units Transfused: | | 4 | | 0 | | | 1 | | |
| Directed Donor Units Transfused: | | 3 | | 7 | | | 10 | | |

Blood Product Usage Report-1997

| | Oct 97 | Nov 97 | Dec 97 |
|---|---------------|---------------|---------------|
| | All Products: | All Products: | All Products: |
| | Cellular: | Cellular: | Cellular: |
| | % of Total: | % of Total: | % of Total: |
| Total Number of Crossmatches | 784 | 709 | 852 |
| Total Number of Transfusions | 495 | 466 | 576 |
| Total Number of Used Crossmatches | 468 | 428 | 543 |
| Percent of Used Crossmatches | 59.69 | 60.37 | 63.73 |
| Total Number of Patients Crossmatched | 222 | 187 | 212 |
| Total Number of Patients Transfused | 158 | 148 | 167 |
| Average Number of Transfusions/Patient | 3.1 | 3.1 | 3.4 |
| Total Number of Single Unit Transfusions | 17 | 23 | 16 |
| Total Number of Patients Tested | 979 | 869 | 961 |
| Products Transfused: | | | |
| Red Blood Cells | 366 | 322 | 424 |
| Irradiated Red Blood Cells | 6 | 3 | 8 |
| Leuko-depleted Red Blood Cells | 80 | 81 | 102 |
| Pedi Leuko-depleted Red Blood Cells | 28 | 40 | 33 |
| Split Red Blood Cells (adult) | 0 | 0 | 0 |
| Washed Red Blood Cells | 0 | 0 | 0 |
| Deglycerolized Red Blood Cells | 0 | 0 | 0 |
| Apheresed Platelets | 41 | 24 | 46 |
| Leuko-depleted Apheresed Platelets | 0 | 2 | 0 |
| Irradiated Apheresed Platelets | 1 | 1 | 0 |
| Random Platelets | 18 | 1 | 0 |
| Irradiated Random Platelets | 0 | 0 | 0 |
| Pediatric Platelets | 6 | 10 | 7 |
| Fresh Frozen Plasma | 82 | 91 | 125 |
| Jumbo Fresh Frozen Plasma | 2 | 0 | 0 |
| Pediatric Fresh Frozen Plasma | 3 | 3 | 0 |
| Cryoprecipitated Anti-hemophilic Factor | 10 | 12 | 5 |
| Pediatric Cryoprecipitated Anti-hemophilic Factor | 0 | 0 | 0 |
| Rh Immune Globulin | 33 | 26 | 36 |
| Rh Immune Globulin-mini dose | 3 | 2 | 2 |
| Autologous Units Transfused: | 6 | 12 | 4 |
| Directed Donor Units Transfused: | 9 | 8 | 5 |

Blood Product Usage report-1999

| | Jan 99 | Feb 99 | March 99 | April 99 | May 99 | June 99 |
|---|----------|----------|----------|----------|----------|----------|
| | Cellular | Cellular | Cellular | Cellular | Cellular | Cellular |
| Total Number of Crossmatches | 751 | 742 | 867 | 791 | 786 | 866 |
| Total Number of Transfusions | 477 | 498 | 545 | 523 | 513 | 561 |
| Total Number of Used Crossmatches | 452 | 478 | 524 | 504 | 548 | 608 |
| Percent of Used Crossmatches | 60.19 | 64.42 | 60.44 | 63.72 | 64.38 | 63.28 |
| Total Number of Patients Crossmatched | 197 | 174 | 211 | 210 | 223 | 223 |
| Total Number of Patients Transfused | 191 | 172 | 156 | 171 | 149 | 165 |
| Average Number of Transfusions/Patient | 3.3 | 6.1 | 3.5 | 3.1 | 3.4 | 3.4 |
| Total Number of Single Unit Transfusions | 12 | 34 | 20 | 18 | 12 | 3.4 |
| C/R Ratio | 1.6:1 | 1.5:1 | 1.6:1 | 1.5:1 | 1.6:1 | 1.7 |
| Total Number of Patients Tested | 871 | 798 | 981 | 907 | 948 | 992 |
| Products Transfused: | | | | | | |
| Red Blood Cells | 363 | 392 | 343 | 337 | 351 | 409 |
| Irradiated Red Blood Cells | 4 | 0 | 0 | 0 | 2 | 2 |
| Leuko-depleted Red Blood Cells | 71 | 76 | 165 | 153 | 145 | 114 |
| Pedi Leuko-depleted Red Blood Cells | 25 | 20 | 24 | 19 | 7 | 14 |
| Split Red Blood Cells (adult) | 2 | 0 | 0 | 0 | 0 | 0 |
| Washed Red Blood Cells | 0 | 2 | 0 | 0 | 0 | 2 |
| Dehydrated Red Blood Cells | 0 | 0 | 0 | 0 | 0 | 0 |
| Dehydrated Platelets | 22 | 25 | 33 | 54 | 47 | 40 |
| Leuko-depleted Apheresed Platelets | 0 | 0 | 0 | 0 | 1 | 0 |
| Irradiated Apheresed Platelets | 0 | 0 | 1 | 0 | 0 | 1 |
| Random Platelets | 0 | 0 | 6 | 0 | 0 | 0 |
| Irradiated Random Platelets | 0 | 0 | 0 | 0 | 0 | 0 |
| Pediatric Platelets | 3 | 4 | 1 | 0 | 0 | 0 |
| Fresh Frozen Plasma | 96 | 488 | 583 | 308 | 191 | 192 |
| Jumbo Fresh Frozen Plasma | 0 | 0 | 0 | 0 | 0 | 0 |
| Pediatric Fresh Frozen Plasma | 3 | 4 | 0 | 0 | 1 | 0 |
| Cryoprecipitated Anti-hemophilic Factor | 0 | 13 | 0 | 20 | 25 | 22 |
| Pediatric Cryoprecipitated Anti-hemophilic Factor | 0 | 0 | 0 | 0 | 0 | 0 |
| Rh Immune Globulin | 34 | 21 | 35 | 29 | 30 | 30 |
| Rh Immune Globulin-mini dose | 0 | 1 | 2 | 0 | 3 | 3 |
| Autologous Units Transfused: | 6 | 2 | 5 | 8 | 6 | 13 |
| Directed Donor Units Transfused: | 6 | 6 | 11 | 6 | 2 | 7 |
| *all apheresed platelets received from ACBB are leukocyte-reduced | | | | | | |

Blood Product Usage Report

| Crossmatched: | Jan 97 | Feb 97 | Mar 97 | Apr 97 | May 97 | June 97 | July 97 |
|----------------------------------|---------------|---------------|---------------|---------------|---------------|----------------|----------------|
| Total Units | 773 | 812 | 872 | 908 | 736 | 814 | 891 |
| Transfused | 342 | 481 | 532 | 606 | 461 | 496 | 596 |
| % Transfused | 44% | 59% | 61% | 63.39% | 62% | 60.93% | 66.89% |
| Type and Screen: | 541 | | | | | | |
| Total # patients crossmatched | | 214 | 231 | 223 | 211 | 254 | 246 |
| Total # patients transfused | | 160 | 171 | 174 | 186 | 221 | 233 |
| Avg # transfusions/patient | | 4.2 | 3.1 | 3.5 | 3.1 | 3.4 | 3.9 |
| Total # single unit transfusions | | 19 | 17 | 24 | 42 | 61 | 55 |
| Total # used crossmatches | | 466 | 515 | 583 | 440 | 456 | 567 |
| Percent of used crossmatches | | 57.39 | 59.06 | 64.21 | 59.78 | 56.02 | 63.64 |
| Transfused: | | | | | | | |
| RBCS | 266 | 347 | 396 | 431 | 362 | 354 | 449 |
| Leuko-depleted RBCS | 76 | 79 | 82 | 113 | 63 | 78 | 85 |
| Pedi Leuko-dep RBCS | 12 | 21 | 18 | 22 | 21 | 38 | 30 |
| Washed RBCS | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deglyced RBCS | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Plateletpheresis | 29 | 33 | 49 | 64 | 34 | 37 | 42 |
| Leukodepleted pheresis | | 3 | 3 | 1 | | 1 | 4 |
| Irradiated plateletpheresis | | | | | | | 4 |
| Random platelets | 1 | 2 | 39 | 39 | 10 | 27 | 30 |
| Pediatric platelets | | | 2 | 0 | 7 | 3 | 16 |
| FFP | 42 | 108 | 138 | 188 | 111 | 122 | 123 |
| Jumbo FFP | | | | 7 | 6 | 0 | 3 |
| Pediatric FFP | | 9 | 7 | 3 | 18 | 1 | 16 |
| Cryoprecipitated AHF | 0 | 37 | 2 | 25 | 26 | 22 | 46 |
| Pediatric cryo | | 1 | 2 | 0 | 0 | 0 | 0 |
| Rh Immune Globulin | | | | 21 | 24 | 31 | 33 |
| Rh Immune Globulin-mini dose | | | | 2 | 2 | 1 | 2 |
| Autologous Units: | | | | | | | |
| Units Ordered | 23 | | | | | | |
| Units Transfused | 6 | 17 | 15 | 24 | 5 | 13 | 12 |
| % Transfused | 26% | | | | | | |
| Directed Donor Units: | | | | | | | |
| Units Ordered | 17 | | | | | | |
| Units Transfused | 8 | 12 | 16 | 14 | 5 | 9 | 6 |
| Irradiated DD units transfused | | | | | | | 8 |
| % Transfused | 47% | | | | | | |
| Total # patients tested | | 907 | 957 | 920 | 1052 | 993 | 1046 |

Blood Product Usage Report-1998

| | Jan 98 | Feb 98 | Mar 98 | Apr 98 | May 98 | Jun 98 |
|---|---------------|---------------|---------------|---------------|---------------|---------------|
| | All Products: | All Products: | All Products: | All Products: | All Products: | All Products: |
| | Cellular: | Cellular: | Cellular: | Cellular: | Cellular: | Cellular: |
| Total Number of Crossmatches | 951 | 820 | 691 | 875 | 831 | 717 |
| Total Number of Transfusions | 605 | 521 | 403 | 536 | 534 | 456 |
| Total Number of Used Crossmatches | 580 | 502 | 387 | 518 | 514 | 454 |
| Percent of Used Crossmatches | 60.99 | 61.22 | 56.01 | 59.20 | 61.85 | 63.32 |
| Total Number of Patients Crossmatched | 222 | 205 | 194 | 217 | 217 | 201 |
| Total Number of Patients Transfused | 169 | 150 | 148 | 163 | 162 | 153 |
| Average Number of Transfusions/Patient | 4.3 | 3.5 | 2.7 | 3.3 | 3.3 | 3.0 |
| Total Number of Single Unit Transfusions | 16 | 17 | 19 | 18 | 18 | 15 |
| C/T Ratio | 18.1 | 16.1 | 17.1 | 12.1 | 16.1 | 18.1 |
| Total Number of Patients Tested | 960 | 855 | 921 | 912 | 972 | 854 |
| Products Transfused: | | | | | | |
| Red Blood Cells | 487 | 399 | 304 | 386 | 422 | 351 |
| Irradiated Red Blood Cells | 7 | 1 | 2 | 7 | 0 | 0 |
| Leuko-depleted Red Blood Cells | 70 | 86 | 62 | 108 | 79 | 96 |
| Ped. Leuko-depleted Red Blood Cells | 26 | 19 | 13 | 17 | 18 | 2 |
| Split Red Blood Cells (adult) | 0 | 0 | 0 | 0 | 0 | 0 |
| Washed Red Blood Cells | 0 | 0 | 0 | 0 | 0 | 0 |
| Deglycerolized Red Blood Cells | 0 | 0 | 0 | 0 | 0 | 0 |
| Apheresed Platelets | 61 | 57 | 26 | 31 | 28 | 26 |
| Leuko-depleted Apheresed Platelets | 0* | 0* | 0* | 0* | 0* | 0* |
| Irradiated Apheresed Platelets | 0 | 0 | 0 | 7 | 0 | 0 |
| Random Platelets | 1 | 0 | 0 | 0 | 0 | 0 |
| Irradiated Random Platelets | 0 | 0 | 0 | 0 | 0 | 0 |
| Pediatric Platelets | 18 | 3 | 3 | 5 | 1 | 0 |
| Fresh Frozen Plasma | 170 | 141 | 91 | 116 | 200 | 84 |
| Jumbo Fresh Frozen Plasma | 0 | 0 | 0 | 0 | 0 | 0 |
| Pediatric Fresh Frozen Plasma | 6 | 0 | 6 | 0 | 2 | 0 |
| Cryoprecipitated Anti-hemophilic Factor | 23 | 12 | 10 | 0 | 29 | 23 |
| Pediatric Cryoprecipitated Anti-hemophilic Factor | 0 | 0 | 0 | 0 | 0 | 0 |
| Rh Immune Globulin | 40 | 23 | 37 | 31 | 33 | 25 |
| Rh Immune Globulin-mini dose | 0 | 2 | 1 | 2 | 1 | 0 |
| Autologous Units Transfused: | | | | | | |
| Autologous Units Transfused: | 9 | 6 | 11 | 11 | 4 | 6 |
| Directed Donor Units Transfused: | 7 | 8 | 13 | 11 | 7 | 1 |
| *all apheresed platelets received from ACBB are leukocyte-reduced | | | | | | |

| | Jun 98 | Jul 98 | Aug 98 | Sep 98 | Oct 98 | Nov 98 | Dec 98 |
|--|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| | Cellular: | Cellular: | Cellular: | Cellular: | Cellular: | Cellular: | Cellular: |
| Total Number of Crossmatches | 717 | 848 | 711 | 785 | 813 | 716 | 813 |
| Total Number of Transfusions | 456 | 544 | 417 | 521 | 507 | 444 | 544 |
| Total Number of Used Crossmatches | 454 | 540 | 415 | 498 | 482 | 423 | 540 |
| Percent of Used Crossmatches | 63.32 | 63.68 | 58.37 | 63.44 | 59.29 | 58.91 | 59.93 |
| Total Number of Patients Crossmatched | 201 | 201 | 204 | 488 | 218 | 193 | 173 |
| Total Number of Patients Transfused | 167 | 212 | 166 | 205 | 198 | 138 | 159 |
| Average Number of Transfusions/Patient | 3.3 | 3.6 | 3.2 | 3.7 | 3.0 | 3.1 | 3.1 |
| Total Number of Single Unit Transfusions | 15 | 17 | 9 | 12 | 10 | 2 | 3 |
| CRT Ratio | 1.1 | 1.6 | 1.7 | 1.5 | 1.6 | 1.6 | 1.6 |
| Total Number of Patients Treated | 654 | 991 | 933 | 1015 | 908 | 870 | 877 |
| Products Transfused: | | | | | | | |
| Red Blood Cells | 351 | 389 | 298 | 377 | 370 | 316 | 249 |
| Irradiated Red Blood Cells | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Concentrates | 98 | 128 | 112 | 107 | 101 | 102 | 92 |
| Platelet Rich Plasma | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Depleted Red Blood Cells | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Whole Blood | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Washed Red Blood Cells | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dehydrated Red Blood Cells | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Apheresis Platelets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leuko-depleted Apheresis Platelets | 28 | 44 | 34 | 28 | 38 | 22 | 22 |
| Irradiated Apheresis Platelets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Random Donor Platelets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Rich Plasma | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Depleted Plasma | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fresh Frozen Plasma | 84 | 149 | 110 | 103 | 124 | 151 | 75 |
| Thawed Fresh Frozen Plasma | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cryoprecipitated Anti-hemophilic Factor | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cryoprecipitated Anti-hemophilic Factor | 23 | 0 | 1 | 2 | 0 | 0 | 0 |
| Pediatric Cryoprecipitated Anti-hemophilic Factor | 0 | 0 | 0 | 60 | 10 | 8 | 0 |
| Rh Immune Globulin | 0 | 0 | 0 | 37 | 34 | 31 | 0 |
| Rh Immune Globulin-imm dose | 0 | 2 | 2 | 0 | 0 | 0 | 0 |
| Autologous Units Transfused: | 6 | 7 | 3 | 5 | 5 | 2 | 3 |
| Directed Donor Units Transfused: | 1 | 5 | 4 | 9 | 2 | 2 | 4 |
| All apheresis platelets received from ACBB are leukocyte-reduced | | | | | | | |

Blood Product Usage Report

| Crossmatched: | Jan 97 | Feb 97 | Mar 97 | Apr 97 | May 97 | June 97 | July 97 | Aug 97 | Sept 97 | Oct 97 | Nov 97 |
|----------------------------------|--------|--------|--------|--------|--------|---------|---------|--------|---------|--------|--------|
| Total Units | 773 | 812 | 872 | 908 | 736 | 814 | 891 | 959 | 784 | 784 | |
| Transfused | 342 | 481 | 532 | 606 | 461 | 496 | 596 | 614 | 475 | 495 | |
| % Transfused | 44% | 59% | 61% | 63.39% | 62% | 60.93% | 66.89% | 64.02% | 67.86% | 63.13% | |
| Type and Screen: | 541 | | | | | | | | | | |
| Total # patients crossmatched | | 214 | 231 | 223 | 211 | 254 | 246 | 232 | 217 | 222 | |
| Total # patients transfused | | 160 | 171 | 174 | 186 | 221 | 233 | 233 | 148 | 158 | |
| Avg # transfusions/patient | | 4.2 | 3.1 | 3.5 | 3.1 | 3.4 | 3.9 | 3.8 | 3.2 | 3.1 | |
| Total # single unit transfusions | | 19 | 17 | 24 | 42 | 61 | 55 | 65 | 43 | 17 | |
| Total # used crossmatches | | 466 | 515 | 583 | 440 | 456 | 567 | 608 | 463 | 468 | |
| Percent of used crossmatches | | 57.39 | 59.06 | 64.21 | 59.78 | 56.02 | 63.64 | 63.40 | 59.06% | 59.69% | |
| Transfused: | | | | | | | | | | | |
| RBCS | 266 | 347 | 396 | 431 | 362 | 354 | 449 | 483 | 375 | 4575 | |
| Irradiated RBCS | | | | | | | | | 14 | | |
| Leuko-depleted RBCS | 76 | 79 | 82 | 113 | 63 | 78 | 85 | 104 | 59 | 1002 | |
| Pedi Leuko-dep RBCS | 12 | 21 | 18 | 22 | 21 | 38 | 30 | 8 | 12 | 283 | |
| Split RBCS (adult) | | | | | | | | | 2 | 0 | |
| Washed RBCS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Deglyced RBCS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Plateletpheresis | 29 | 33 | 49 | 64 | 34 | 37 | 42 | 46 | 30 | 475 | |
| Leukodepleted pheresis | 0 | 3 | 3 | 1 | 0 | 1 | 4 | 0 | 0 | 14 | |
| Irradiated plateletpheresis | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 5 | 7 | 18 | |
| Random platelets | 1 | 2 | 39 | 39 | 10 | 27 | 30 | 0 | 32 | 199 | |
| Random platelets-irradiated | | | | | | | | | 7 | 7 | |
| Pediatric platelets | 0 | 0 | 2 | 0 | 7 | 3 | 16 | 1 | 1 | 54 | |
| FFP | 42 | 108 | 138 | 188 | 111 | 122 | 123 | 155 | 112 | 1327 | |
| Jumbo FFP | 0 | 0 | 0 | 7 | 6 | 0 | 3 | 4 | 3 | 525 | |
| Pediatric FFP | 0 | 9 | 7 | 3 | 18 | 1 | 16 | 0 | 0 | 60 | |
| Cryoprecipitated AHF | 0 | 37 | 2 | 25 | 26 | 22 | 46 | 20 | 1 | 211 | |
| Pediatric cryo | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | |
| Rh Immune Globulin | | | | 21 | 24 | 31 | 33 | 45 | 29 | | |
| Rh Immune Globulin-mini dose | | | | 2 | 2 | 1 | 2 | 2 | 3 | | |
| Autologous Units: | | | | | | | | | | | |
| Units Ordered | 23 | | | | | | | | | | |
| Units Transfused | 6 | 17 | 15 | 24 | 5 | 13 | 12 | 10 | 4 | 128 | |
| % Transfused | 26% | | | | | | | | | | |
| Directed Donor Units: | | | | | | | | | | | |
| Units Ordered | 17 | | | | | | | | | | |
| Units Transfused | 8 | 12 | 16 | 14 | 5 | 9 | 6 | 2 | 5 | 99 | |
| Irradiated DD units transfused | | | | | | | 8 | 2 | 3 | 13 | |
| % Transfused | 47% | | | | | | | | | | |
| Total # patients tested | | 907 | 957 | 920 | 1052 | 993 | 1046 | 1007 | 871 | | |

Autogenic Rhos 5591

L/D Rhos 1002
Pedi 283
14
1299

1002
283
1285

Brookwood Medical Center
Chart Audit Action Plan – ACCURACY

MONTH - MARCH, 2000

| Department | Blood & Blood Derivative | Percent |
|------------------------------|--------------------------|--------------|
| | | |
| Total Charges Audited | 23,050.10 | 21.16 |
| | | |
| Overcharges | 2,781.40 | (12.06) |
| | | |
| Under Charges | 2,097.20 | 9.09 |
| | | |

Reason for variance:

The variances are from two sources:

1. Problem: Patient Basil, Murphy had orders placed on an account other than the right admitting account (8292161 VS 8291031).

2. Problem: Patient James Brock had several issues that need follow-up. In short, there seems to be some problems with the billing set-ups that do not explain some charges!

Plan for Improvement:

1. Corrective action: This problem will be conveyed to admitting as well as cancer center to figure out a preventive solution.

2. Corrective action: This problem will be addressed with information systems as well as the billing department (cost accounting).

COMPLETED BY: Emad Balkash Transfusion service
Clinical coordinator

DATE: 04/17/00

Attach additional information if necessary.

ALL SHEETS MUST BE RETURNED TO JOYCE TROTT BY THE 15TH OF THE MONTH.



Memorandum

To: To all blood bank staff

CC:

From: Emad Balkash

Date: May, 08, 2000

Re: Filter charges

Effective immediately, Filter charges have been changed to the following:

- No charges should be made to any Y- set filter of any product issued (PC, PP FP, and CR etc.), including baby's aliquots.
- Charge Z\$RBCFI (or 29943 in HBOC) for **PC leukocyte filter** (in the case unit is not prestored leukocyte reduced and the order asks for leukocyte reduced PC).
- Charge Z\$LDFIL (or 29944 in HBOC) for **platelet (PP) leukocyte filter**. This filter is required only when component is ordered leukocyte reduced and the component given is either pooled component or PP that is not leukocyte reduced already.

CONFIDENTIAL